See the DrugPatentWatch profile for vascepa

Based on the available information from the provided sources, the criteria to determine Vascepa (icosapent ethyl) eligibility include:

1. Indication: Vascepa is indicated for reducing the risk of cardiovascular events in adults with elevated triglyceride levels (18 years and older) ([1][2]). Specifically, it is for patients with triglyceride levels of 150 mg/dL or higher who are already on a statin medication and have either established cardiovascular disease or diabetes and two or more additional risk factors for cardiovascular disease ([3]).

2. Age: As mentioned, Vascepa is for adults aged 18 years and older ([1][2]).

3. Contraindications: Patients with known hypersensitivity to icosapent ethyl or any component of the Vascepa formulation should not use the medication ([1][2]).

4. Caution: Vascepa should be used with caution in patients with hepatic impairment, as there is limited data on its safety and efficacy in these patients ([1][2]).

5. Pregnancy and lactation: Vascepa is classified as Pregnancy Category C, which means it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus ([1][2]). It is not known if Vascepa is excreted in human milk, so caution should be exercised when administering the drug to nursing women ([1][2]).

Please consult a healthcare professional for a comprehensive evaluation of a patient's eligibility for Vascepa.

Sources:
[1] <https://www.vascepa.com/>
[2] <https://www.drugpatentwatch.com/p/tradename/VASCEPA>
[3] <https://www.va.gov/formularyadvisor/DOC_PDF/Icosapent_Ethyl_Vascepa_for_Reducing_CV_Risk_Mar2021.pdf>